Presentation is loading. Please wait.

Presentation is loading. Please wait.

Environmental Sustainability at Novartis

Similar presentations


Presentation on theme: "Environmental Sustainability at Novartis"— Presentation transcript:

1 Environmental Sustainability at Novartis
Novartis North American HSE & BC 2013 ISPE- NJ Supplier Showcase, September 12

2 We work responsibly and ethically
Our patients and customers expect us to do business responsibly and ethically. We want to work with others to help address some of the world’s biggest health challenges. We focus our corporate responsibility work in three areas: Reaching more patients Collaborating for results Doing business responsibly 1 2 3 Expanding access to healthcare R&D for rare and neglected diseases Malaria Initiative Leprosy elimination Social business models: Arogya Parivar Listening to and working with our stakeholders Stakeholder engagement NGO relationships Novartis perspectives and positions Striving for operational excellence Caring for our associates Protecting the environment Promoting ethics and strengthening governance We aim to improve global health. Through our business, we make an important contribution to society: We discover and develop innovative healthcare products, targeting unmet medical needs. Our patients and customers need to trust us and our products. They expect us to do business responsibly and ethically. 2 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

3 Access-to-medicine programs – in 2011 we supported 89 million patients
Coartem® delivered without profit More than 80 million malaria patients treated 2011 Programs and research valued at USD 1.7 bn3 Contributed 3% of net sales Leprosy medicine donated through WHO Extended donation agreement to 2020 Tuberculosis medicine donations More than 100,000 treatments delivered Glivec®/Tasigna® patient assistance Provided to 47,000 patients in about 80 countries NITD1 in Singapore Focus on tuberculosis, dengue fever and malaria Novartis works to ensure that life-saving medicines are accessible to patients in a variety of ways. We provide our antimalarial medicine Coartem without profit in developing countries We are fighting leprosy and tuberculosis in developing countries through innovative partnerships with the WHO. We offer our innovative cancer medicine, Glivec, at reduced cost or free to patients who would otherwise not be able to afford it. We also work to break down barriers to access, including access to treatment centers and acceptability of treatment, through the Novartis Foundation for Sustainable Development. Two nonprofit research institutes, NITD and NVGH, research neglected diseases of the developing world, and commit to make treatments available to patients in poor countries without profit. Novartis continues our commitment to support patients through programs valued at USD 1.7 billion, or 3% of net sales NVGH2 in Siena, Italy Vaccines research institute for neglected diseases 1Novartis Institute for Tropical Diseases; 2Novartis Vaccines Institute for Global Health; 3Based on approximate market value 3 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

4 Novartis Code of Conduct and HSE mission
Novartis Health, Safety and Environment Mission To be a leader in health, safety and environmental protection, as an integral part of the business, for the benefit of our associates and other stakeholders Environment in the Code of Conduct We make efficient use of natural resources and minimize the environmental impact of our activities and products over their life cycle. 4 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

5 The value added by HSE & BCM
5 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

6 Commitment to the environment
“Protecting the environment is an integral part of business strategy in all divisions and business units. By balancing our economic, social and environmental objectives we aim to have a long term sustainable business.” Keith Saveal Head Corporate HSE, Novartis 6 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

7 Product value chain TechOps
Business process functions manage the value chain: Research Development Procurement Manufacturing Infrastructure Distribution Marketing & Sales CommOps Up-streams Down-streams Raw Materials Inter- mediates Supply TechOps Delivery Product Use End of Life 7 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

8 Mapping relevant environmental aspects
NVS Operations Delivery Product Use End of Life Inter- mediates Supply Raw Materials Sustainable Packaging Materials Water Energy GHG Pr. Subs. Air Emis. Effluents Waste Contamin. Energy Efficiency Energy & Climate Energy Climate PiE PiE Legacy sites 8 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

9 Why Environmental Footprint over the Live Cycle?
Growing interest in environmental impacts outside the company boundary Requests for information on supply chain from stakeholders and sustainability rating agencies Stakeholder concerns related to potential environmental impacts (micro- pollutants) from pharmaceutical product use and disposal Trends with respect to increasing outsourcing and change of production patterns Globalization of business and of the value chain In 2009 we did a Scope 3 GHG emission estimation for Novartis overall with following results: Raw material generation may represent the largest carbon impact Other relevant impacts are waste disposal, infrastructure, business travel and packaging material disposal 9 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

10 Objectives for our Life Cycle Assessment (LCA) work
Gain better understanding of impacts (carbon, waste, water, eco- toxicity, etc.) and assessment methodologies Learn how to use tools effectively Develop an understanding of relevant influencing factors and product specific parameters that determine the impact Raise awareness for these factors and how they can be influenced in the business Find ways to reduce relevant life cycle impacts for the benefit of clients, the company and the environment 10 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

11 Life Cycle Analysis Learning
What did we learn from Cradle-to-grave LCA / Supply Chain Carbon Footprint: Pharma product impact overall is small: 10kg CO2e for annual patient dose = driving 35km Impact from materials (solvents, intermediates) purchased from the supply chain is dominant (60%) Potential end-of-live impact (Pharmaceuticals in the Environment) is not well reflected in a Carbon Footprint analysis Internal transportation and distribution (for high volume products) are marginal What did we learn from Cradle-to-gate Carbon Footprinting for APIs: Synthetic APIs have a clearly higher impact than Bio-tech APIs (170 versus 17tCO2e/t) Energy is the dominant factor in Bio-tech (80%) Supply chain and internal transportation are marginal (2%) 11 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

12 Influencing factors What type of API generation do we have (synthetic versus fermentation/bio-tech)? What is the molecule (how complex is its chemical synthesis)? What is the physiological activity of the molecule (what is the dose required)? What (supply and distribution) logistics have we chosen? What is the environmental effect potential after use (PiE); what measures are necessary to keep the environmental impact marginal? Which improvements count the most? 12 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

13 Green Chemistry Designing more sustainable medications
ACS GCI Roundtable Green chemistry in practice Telescoping Solvent elimination Supply Chain Green Solvents Critical mass "No endorsement or approval by the ACS GCI Pharmaceutical Roundtable has been received or is in any way implied." 13 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

14 Environment and Energy Strategic Objectives
Pharmaceuticals in the Environment Minimize risk related to Pharmaceuticals in the Environment (PiE) Leader in environmental sustainability Leading position on energy and climate Stringent management of environmental liabilities and legal compliance Sustainable packaging GHG emission reductions and Carbon offsetting Contaminated sites 14 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

15 Pharmaceuticals in the Environment
Novartis Position Minimize environmental impact of activities and products over life cycle; work with suppliers No risk for human health; implications for aquatic wildlife limited or inconclusive Four-fold strategy, applies to all operations involved in R&D, production and disposal Environmental risk assessment: evaluate impact of new products before reaching the marketplace Manufacturing: minimize discharge of APIs from operations; take appropriate corrective measures Save disposal: do not dispose waste containing APIs into landfills; recommend avoiding disposal into sewers or landfills; welcome state-of-art waste water treatment and processes/system to ensure incineration Increase knowledge: support academia and regulators to close data gaps 15 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

16 Three pathways into the environment
Upgrade of public waste water treatment Patient use Excretion, washing off the skin Hospitals / retirement homes Extent of metabolization Collection / take-back schemes, consumer education Incorrect disposal Toilet flushing Landfill of household waste Take-back schemes (e.g. Spain) Site special waste water treatment, operational measures Factory effluents ChemOps, PharmOps sites API suppliers and formulation contractors 16 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

17 Novartis Vision on Sustainable Packaging
“Consistent with our goal to be the most respected health care company, Novartis will design and utilize packaging solutions that minimize the impact on the environment while meeting all design, functional, regulatory and quality requirements that our patients and customers expect.” Developed by the Sustainable Packaging Committee, approved by HSE SteCom and endorsed by ECN in Nov 2010 17 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

18 Savings achieved with packaging improvements
Savings from 20 projects between 2008 and 2012 Cost USD 2.7mio Materials 572t of carton / plastic / metals GHG emissions more than 133tCO2e Other 30% weight reduction Storage space Lead time Work load Waste 18 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

19 Elimination of plastics in Lamisil Gel packaging
BEFORE High-end package with a strong visual statement Very complex and labor intensive AFTER Several re-designs of package leading to USD 189,000 of cost saved Complete elimination of plastics Reduced packaging complexity Overall high-impact appearance of the product kept 19 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

20 Design guide on Sustainable Packaging
Principles of Sustainable Packaging Material selection Choose materials with lower environmental impact Reduce number of different materials Design and size of the package Reduce total amount of materials Reduce excess volume Reduce number of layers Procurement of packaging materials Purchase from environmentally and socially responsible suppliers Consider certified/preferred materials Consider local sources Specific questions on each level of packaging Primary packaging Secondary packaging Tertiary packaging 20 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

21 Energy and climate: commitment and targets
In 2001, Novartis joined the UN Global Compact In 2004, Voluntary “Kyoto” target set for global direct CO2 emissions: Emit 5% less greenhouse gases (GHGs) by 2012 than in 1990; i.e. <293kt of Scope 1 on-site GHG emissions In 2010, mid-term 15% reduction of total GHGs (Scope1 and Scope 2) by 2015, and long-term 20% reduction by 2020, based on 2008 levels To achieve these targets, Novartis employs a dual strategy Improve energy efficiency and make use of renewable resources in order to keep energy use and GHG emissions at a minimum Engage and participate in “carbon offset“ projects (sequestration) in order to compensate for part of the Novartis GHG emissions 21 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

22 Successful energy savings by project Novartis Group Energy Use and Energy Savings by Projects
Energy use and savings (in TJ) target 2015: 14.0% status 2012: 11.5% Energy costs and cost savings (in million USD)  2150TJ  USD 57mio 22 | Environmental Sustainability at Novartis| August 2013| Business Use Only

23 Energy Excellence Awards
Proven success with the Energy Excellence Awards (EEA) over last years In eight years, the EEA scheme has: Generated over 500 projects totaling more than USD 100 million in cost savings Saved 4,000 terajoules 350 kiloton reduction of GHG, which equals the total emissions of the Novartis Group’s vehicles over 2 years Created tangible, replicable best practices The awards are perceived as a highly prestigious prize with senior management support Associates are motivated to “compete with the best” 23 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

24 Planting trees to capture CO2 and foster biodiversity
3 mio in Argentina 9 mio in China by 2014 4 Mt of carbon over 30 years Natural forests primarily based on native species Wood product business managed by principles of the Forest Stewardship Council Two UN registered projects (Argentina, China) one VCS (Mali) Social and environmental benefits Improve boiler KPIs 12 mio trees 24 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

25 Contributing to rural development in Mali with plantation of Jatropha
5,000ha of Jatropha planted by more than 5,000 local farmers 200kt of carbon by 2020 Jatropha oil used for rural electrification, soap, bio-fertilizer by-product Supplemental income for farmers Protects food crops Protects fields from soil erosion and counters desertification 25 | Environmental Sustainability at Novartis | August 2013 | Business Use Only

26 2012 Kyoto target achieved Novartis on-site Scope1 GHG emissions by 2012 (excl. Alcon) are 5% below 1990, i.e.: 293kt Results: Emissions: 2012 emission were 409kt. The needs from offset projects is therefore at least 116kt. Offsets: Argentina reached 118kt by year end The Mali project gave only about 1.1kt offsets. Result: Emissions = 409kt Offsets = 119kt Balance = 290kt Kyoto target achieved! kt Offsets Kyoto target Scope1 GHG 26 | Environmental Sustainability at Novartis | August 2013| Business Use Only


Download ppt "Environmental Sustainability at Novartis"

Similar presentations


Ads by Google